

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2012296905 B2**

- (54) Title
Combination therapy with an anti - CD19 antibody and a purine analog
- (51) International Patent Classification(s)
C07K 16/28 (2006.01) **A61K 39/395** (2006.01)
- (21) Application No: **2012296905** (22) Date of Filing: **2012.08.14**
- (87) WIPO No: **WO13/024095**
- (30) Priority Data
- | | | |
|-------------------|-------------------|--------------|
| (31) Number | (32) Date | (33) Country |
| 61/523,862 | 2011.08.16 | US |
| 11177660.5 | 2011.08.16 | EP |
- (43) Publication Date: **2013.02.21**
- (44) Accepted Journal Date: **2017.01.05**
- (71) Applicant(s)
MorphoSys AG
- (72) Inventor(s)
Amersdorffer, Jutta;Steidl, Stefan;Winderlich, Mark;Krohn, Susanne;Rojkjaer, Lisa
- (74) Agent / Attorney
Shelston IP Pty Ltd., Level 21, 60 Margaret Street, Sydney, NSW, 2000
- (56) Related Art
KOCHENDERFER J. et al, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, 2010, Vol. 116(20), pp 4099-4102



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)
- (21) **International Application Number:**
PCT/EP2012/065904
- (22) **International Filing Date:**
14 August 2012 (14.08.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
11177660.5 16 August 2011 (16.08.2011) EP
61/523,862 16 August 2011 (16.08.2011) US
- (71) **Applicant (for all designated States except US):**
MORPHOSYS AG [DE/DE]; Lena-Christ-Strasse 48,
82152 Martinsried/Planegg (DE).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **AMERSDORFFER, Jutta** [DE/DE]; Lena-Christ-Str. 48, 82152 Martinsried / Planegg (DE). **STEIDL, Stefan** [DE/DE]; Ebenböckstr. 25, 81241 München (DE). **WINDERLICH, Mark**

[DE/DE]; Implersstr. 52, 81371 München (DE). **KROHN, Susanne** [DE/DE]; Haidelweg 22a, 81241 München (DE). **ROJKJAER, Lisa** [CA/CH]; Frohmossstrasse 38h, CH-8908 Hedingen (CH).

- (74) **Agent:** **HUTTER, Bernd**; Lena-Christ-Str. 48, 82152 Planegg-Martinsried (DE).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,

[Continued on next page]

- (54) **Title:** COMBINATION THERAPY WITH AN ANTI - CD19 ANTIBODY AND A PURINE ANALOG

Figure 5

Normalized specific killing; SD; MEC-1 target cells pretreated with Fludarabine (Flu) for 72 h before ADCC; pool of 3 independent experiments with 3 different effector cell donors



The figure shows the averages from the data shown in Table 2.

(57) **Abstract:** The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.



UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

COMBINATION THERAPY WITH AN ANTI - CD19 ANTIBODY AND A PURINE ANALOG

Cross reference

This application claims the benefit of U.S. provisional application serial number US 61/523,862 filed August 16, 2011, which is incorporated by reference in its entirety.

Field of the Invention

The present disclosure is related to a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

Background

B cells are lymphocytes that play a large role in the humoral immune response. They are produced in the bone marrow of most mammals, and represent 5-15% of the circulating lymphoid pool. The principal function of B cells is to make antibodies against various antigens, and are an essential component of the adaptive immune system.

Because of their critical role in regulating the immune system, dysregulation of B cells is associated with a variety of disorders, such as lymphomas, and leukemias. These include non-Hodgkin's lymphoma (NHL), chronic lymphoid leukemia (CLL) and acute lymphoblastic leukemia (ALL).

NHL is a heterogeneous malignancy originating from lymphocytes. In the United States (U.S.), the incidence is estimated at 65,000/year with mortality of approximately 20,000 (American Cancer Society, 2006; and SEER Cancer Statistics Review). The disease can occur in all ages, the usual onset begins in adults over 40 years, with the incidence increasing with age. NHL is characterized by a clonal proliferation of lymphocytes that accumulate in the lymph nodes, blood, bone marrow and spleen, although any major organ may be involved. The current classification system used by pathologists and clinicians is the World Health Organization (WHO) Classification of Tumours, which organizes NHL into precursor and mature B-cell or T-cell neoplasms. The PDQ is currently dividing NHL as indolent or aggressive for entry into clinical trials. The indolent NHL group is comprised primarily of follicular subtypes, small lymphocytic lymphoma, MALT (mucosa-associated lymphoid tissue), and marginal zone; indolent encompasses approximately 50% of newly diagnosed B-cell NHL patients. Aggressive NHL includes patients with histologic diagnoses of primarily diffuse large B cell (DLBL, DLBCL, or DLCL) (40% of all newly diagnosed patients have diffuse large cell), Burkitt's, and mantle cell. The clinical course of NHL is highly variable. A major determinant of clinical course is the histologic subtype. Most indolent types of NHL are considered to be incurable disease. Patients respond initially to either chemotherapy or antibody therapy and most will relapse.

Studies to date have not demonstrated an improvement in survival with early intervention. In asymptomatic patients, it is acceptable to "watch and wait" until the patient becomes symptomatic or the disease pace appears to be accelerating. Over time, the disease may transform to a more aggressive histology. The median survival is 8 to 10 years, and indolent patients often receive 3 or more treatments during the treatment phase of their disease. Initial treatment of the symptomatic indolent NHL patient historically has been combination chemotherapy. The most commonly used agents include: cyclophosphamide, vincristine and prednisone (CVP); or cyclophosphamide, adriamycin, vincristine, prednisone (CHOP). Approximately 70% to 80% of patients will respond to their initial chemotherapy, duration of remissions last on the order of 2-3 years. Ultimately the majority of patients relapse. The discovery and clinical use of the anti-CD20 antibody, rituximab, has provided significant improvements in response and survival rate. The current standard of care for most patients is rituximab + CHOP (R-CHOP) or rituximab + CVP (R-CVP). Interferon is approved for initial treatment of NHL in combination with alkylating agents, but has limited use in the U.S. Rituximab therapy has been shown to be efficacious in several types of NHL, and is currently approved as a first line treatment for both indolent (follicular lymphoma) and aggressive NHL (diffuse large B cell lymphoma). However, there are significant limitations of anti-CD20 monoclonal antibody (mAb), including primary resistance (50% response in relapsed indolent patients), acquired resistance (50% response rate upon re-treatment), rare complete response (2% complete response rate in relapsed population), and a continued pattern of relapse. Finally, many B cells do not express CD20, and thus many B-cell disorders are not treatable using anti-CD20 antibody therapy.

In addition to NHL there are several types of leukemias that result from dysregulation of B cells. Chronic lymphocytic leukemia (also known as "chronic lymphoid leukemia" or "CLL"), is a type of adult leukemia caused by an abnormal accumulation of B lymphocytes. In CLL, the malignant lymphocytes may look normal and mature, but they are not able to cope effectively with infection. CLL is the most common form of leukemia in adults. Men are twice as likely to develop CLL as women. However, the key risk factor is age. Over 75% of new cases are diagnosed in patients over age 50. More than 10,000 cases are diagnosed every year and the mortality is almost 5,000 a year (American Cancer Society, 2006; and SEER Cancer Statistics Review). CLL is an incurable disease but progresses slowly in most cases. Many people with CLL lead normal and active lives for many years. Because of its slow onset, early-stage CLL is generally not treated since it is believed that early CLL intervention does not improve survival time or quality of life. Instead, the condition is monitored over time. Initial CLL treatments vary depending on the exact diagnosis and the progression of the disease. There are dozens of agents used for CLL therapy. Combination chemotherapy regimens such as FCR (fludarabine, cyclophosphamide and rituximab), and BR (bendamustine and rituximab) are effective in both newly-diagnosed and relapsed CLL. Allogeneic bone marrow (stem cell)

transplantation is rarely used as a first-line treatment for CLL due to its risk.

Another type of leukemia is acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia. ALL is characterised by the overproduction and continuous multiplication of malignant and immature white blood cells (also known as lymphoblasts) in the bone marrow. 'Acute' refers to the undifferentiated, immature state of the circulating lymphocytes ("blasts"), and that the disease progresses rapidly with life expectancy of weeks to months if left untreated. ALL is most common in childhood with a peak incidence of 4-5 years of age. Children of age 12- 16 die more easily from it than others. Currently, at least 80% of childhood ALL are considered curable. Under 4,000 cases are diagnosed every year and the mortality is almost 1,500 a year (American Cancer Society, 2006; and SEER Cancer Statistics Review).

The human CD 19 molecule is a structurally distinct cell surface receptor expressed on the surface of human B cells, including, but not limited to, pre-B cells, B cells in early development (i.e., immature B cells), mature B cells through terminal differentiation into plasma cells, and malignant B cells. CD 19 is expressed by most pre-B acute lymphoblastic leukemias (ALL), non-Hodgkin's lymphomas, B cell chronic lymphocytic leukemias (CLL), pro-lymphocytic leukemias, hairy cell leukemias, common acute lymphocytic leukemias, and some Null-acute lymphoblastic leukemias (Nadler et al, J. Immunol., 131 :244-250 (1983), Loken et al, Blood, 70:1316-1324 (1987), Uckun et al, Blood, 71 :13- 29 (1988), Anderson et al, 1984. Blood, 63:1424-1433 (1984), Scheuermann, Leuk. Lymphoma, 18:385-397(1995)). The expression of CD 19 on plasma cells further suggests it may be expressed on differentiated B cell tumors such as multiple myeloma, plasmacytomas, Waldenstrom's tumors (Grossbard et al., Br. J. Haematol, 102:509- 15(1998); Treon et al, Semin. Oncol, 30:248-52(2003)).

Therefore, the CD 19 antigen is a target for immunotherapy in the treatment of non-Hodgkin's lymphoma (including each the subtypes described herein), chronic lymphocytic leukemia and/or acute lymphoblastic leukemia. CD19 has also been suggested as a target for immunotherapy in the treatment of autoimmune disorders in WO2000074718, which is incorporated by reference in its entirety.

Certain CD19 therapies have been shown. T cells expressing an anti-CD19 chimeric antigen receptor (CAR) including both the CD3- ζ and CD28 molecules were administered to a patient having follicular lymphoma. Kochenderfer et al., Eradication of B lineage cell and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, vol. 116, no: 20 (November 2010). Sadelain et al., The promise and potential pitfalls of chimeric antigen receptors, Current Opinion in Immunology, Elsevier, vol. 21, no.2, 2 April 2009, which is incorporated by reference in its entirety, also describes anti-CD19 chimeric antigen receptors (CARs). Rosenberg et al, Treatment of B cell Malignancies with T cells expressing an

anti-CD19 chimeric receptor: Assessment of the Impact of Lymphocyte Depletion Prior to T cell Transfer, (September 2008), [www.gemcris.od.nih.gov/ Abstracts/940_s.pdf](http://www.gemcris.od.nih.gov/Abstracts/940_s.pdf) (retrieved on 13 Jan 2012), which is incorporated by reference in its entirety, describes anti-CD19 chimeric antigen receptors (CARs) used with fludarabine. See also Eshhar et al., Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, D.C., vol. 90, no.2 (15 January 1993). Neither Kochenderfer et al., Sadelain et al., Rosenberg et al., nor Eshhar et al., however, describe the antibody specific for CD19 in combination with fludrabine as exemplified herein.

Fludarabine as a therapy in the treatment of CLL was described in Montserrat et al., Chronic lymphocytic leukemia treatment, Blood Review, Churchill Livingstone, vol. 7, no. 3 (1 Sept. 1993), but does not suggest the antibody specific for CD19 in combination with fludrabine as exemplified herein.

The use of a CD19 antibody in B cell disorders is discussed in US2011104150, which is incorporated by reference in its entirety, along with the cursory mention of fludarabine within a long list of potential combination partners, but fails either to teach the exemplified antibody or to suggest the synergistic effects of the combination in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia as exemplified herein.

The use of a CD19 antibody in non-specific B cell lymphomas is discussed in WO2007076950, which is incorporated by reference in its entirety, along with the cursory mention of fludarabine within a long list of potential combination partners, but fails either to teach the exemplified antibody or suggest the synergistic effects of the combination in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia as exemplified herein.

The use of a CD19 antibody in leukemias and lymphomas is discussed in WO2005012493, which is incorporated by reference in its entirety, along with the cursory mention of fludarabine within a long list of potential combination partners, but fails either to teach the exemplified antibody or suggest the synergistic effects of the combination in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia as exemplified herein.

The use of a CD19 antibody in CLL, NHL and ALL is described in Scheuermann et al., CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy, Leukemia and Lymphoma, Vol. 18, 385-397 (1995), which is incorporated by reference in its entirety, but fails to suggest the combination exemplified herein.

Additional antibodies specific for CD19 are described in WO2005012493 (US7109304), WO2010053716 (US12/266,999) (Immunomedics); WO2007002223 (US US8097703) (Medarex); WO2008022152 (12/377,251) and WO2008150494 (Xencor), WO2008031056 (US11/852,106) (Medimmune); WO 2007076950 (US 11/648,505) (Merck Patent GmbH); WO 2009/052431

(US12/253,895) (Seattle Genetics); and WO2010095031 (12/710,442) (Glenmark Pharmaceuticals), which are all incorporated by reference in their entireties.

Combinations of antibodies specific for CD19 and other agents are described in WO2010151341 (US 13/377,514) (The Feinstein Institute); US5686072 (University of
5 Texas), and WO2002022212 (PCT/US01/29026) (IDEC Pharmaceuticals), which are all incorporated by reference in their entireties.

It is clear that in spite of the recent progress in the discovery and development of anti-cancer agents, many forms of cancer involving CD19-expressing tumors still have a poor prognosis. Thus, there is a need for improved compositions and methods for
10 treating such forms of cancer.

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

15 **Summary**

According to a first aspect, the present invention provides a method for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia in a subject comprising administering to the subject a synergistic combination of:

20 an antibody specific for CD19; and
fludarabine,

wherein the antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence
25 RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).

According to a second aspect, the present invention provides use of a synergistic combination of:

30 an antibody specific for CD19; and
fludarabine,

for the manufacture of a medicament for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia,

wherein the antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence
35

RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).

Unless the context clearly requires otherwise, throughout the description and the claims, the words "comprise", "comprising", and the like are to be construed in an
5 inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".

Neither alone nor in combination does the prior art suggest the synergistic effects of the combination of the exemplified antibody and fludarabine in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic
10 leukemia.

In another aspect, the present disclosure relates to a synergistic combination of an antibody specific for CD19 and a purine analog. Such combinations are useful in the treatment of B cell malignancies, such as, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

15 In vitro and in vivo models are considered indicative of how a certain compound or combination of compounds would behave in humans. In addition, when compounds are combined either in vitro or in vivo, one expects that the combination has only additive effects. Surprisingly, the inventors found that the combination of a particular antibody specific for CD19 and fludarabine mediated a synergistic level of specific cell
20 killing in a chronic B-cell leukemia cell line (MEC-1) in comparison to the antibody and fludarabine alone. This in vitro model is indicative of how the combination will work in the treatment of chronic lymphoid leukemia (CLL) in humans. In addition, and also unexpectedly, the inventors found that the combination of a particular antibody specific for CD19 and fludarabine synergistically inhibited tumor growth and synergistically
25 increased median survival days, both in Burkitt's lymphoma SCID mouse models, in comparison to the antibody and fludarabine alone. These in vivo models are indicative of how the combination will work in the treatment of non-Hodgkin's lymphoma in humans. In summary, the combination of the exemplified anti-CD19 antibody and fludarabine behaved synergistically in models relevant to NHL and CLL. As both NHL
30 and CLL are B cell related disorders and CD19 is highly expressed on B-cells, the exemplified combination would have the same mechanism of action and should also behave synergistically in the treatment of other B cell related disorders, e.g. ALL.

Therefore, the combination of the exemplified antibody specific for CD19 and fludarabine _____

will be effective in the treatment of humans in non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia. In addition, the antibody specific to CD19 exemplified in the present specification has already entered into clinical trials, where such combinations can be confirmed in humans.

As the mechanism of action of fludarabine and other purine analogs are similar, as purine analogs interfere with the synthesis of nucleic acids, it is believed that synergy should also be seen when treating humans having non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia with a combination of the exemplified anti-CD19 antibody and a purine analog other than fludarabine.

As the exemplified anti-CD19 antibody and other anti-CD19 antibodies bind CD19, it is believed that synergy should also be seen when treating humans having non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia with a combination of any anti-CD19 antibody and a purine analog, e.g., fludarabine.

As the exemplified anti-CD19 antibody binds a specific epitope of CD19, it is believed that antibodies that cross-compete with the exemplified antibody or bind to the same epitope as the exemplified antibody should also behave synergistically when treating humans having non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia in combination with a purine analog, e.g., fludarabine.

An aspect of the present disclosure comprises a synergistic combination wherein the antibody specific for CD19 comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6) and fludarabine. In preferred aspects, the combination is used for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

Description of Drawings

Figure 1 shows the cytotoxicity effects of MOR208 and fludarabine alone and in combination on MEC-1 cells.

Figure 2 shows the ADCC dose response curves of the combination of MOR208 and fludarabine in MEC-1 cells.

Figure 3 shows the amino acid sequence of the variable domains of MOR208.

Figure 4 shows the amino acid sequence of the Fc regions of MOR208.

Figure 5 shows the normalized specific killing of MEC-1 target cells pretreated with Fludarabine (Flu) for 72 h. The data represents a pool of 3 independent experiments with 3 different effector cell donors.

Figure 6 shows the mean tumor growth of the MOR208, FLU, and combination (MOR208/FLU) groups of the SCID mouse model described in Example 2.

Figure 7 shows median survival time of the MOR208, FLU, and combination (MOR208/FLU) groups of the SCID mouse model described in Example 3.

Detailed description of the invention

"Synergy", "synergism" or "synergistic" mean more than the expected additive effect of a combination. The "synergy", "synergism" or "synergistic" effect of a combination is determined herein by the methods of Chou et al., Clarke et al., and/or Webb et al. See Ting-Chao Chou, Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies, *Pharmacol Rev* 58:621–681 (2006), which is incorporated by reference in its entirety. See also Clarke et al., Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents *in vivo* in breast cancer and other models, *Breast Cancer Research and Treatment* 46:255-278 (1997), which is incorporated by reference in its entirety. See also Webb, J. L. (1963) *Enzyme and Metabolic Inhibitors*, Academic Press, New York, which is incorporated by reference in its entirety.


The term "antibody" means monoclonal antibodies, including any isotype, such as, IgG, IgM, IgA, IgD and IgE. An IgG antibody is comprised of two identical heavy chains and two identical light chains that are joined by disulfide bonds. Each heavy and light chain contains a constant region and a variable region. Each variable region contains three segments called "complementarity-determining regions" ("CDRs") or "hypervariable regions", which are primarily responsible for binding an epitope of an antigen. They are referred to as CDR1, CDR2, and CDR3, numbered sequentially from the N-terminus. The more highly conserved portions of the variable regions outside of the CDRs are called the "framework regions". An "antibody fragment" means an Fv, scFv, dsFv, Fab, Fab' F(ab')₂ fragment, or other fragment, which contains at least one variable heavy or variable light chain, each containing CDRs and framework regions.

A purine analog is an antimetabolite, which mimics the structure of metabolic purines, thereby interfering with the synthesis of nucleic acids. Fludarabine, for example, may be incorporated into RNA and DNA by substituting for the purine nucleotides, adenine and guanine. Purine analogs inhibit growth of fast proliferating cells of an individual, e.g. cancer cells, bone marrow cells or cells


present in the gastrointestinal tract. Purine analogs include mercaptopurine, azathioprine, thioguanine and fludarabine.

Mercaptopurine is used in the treatment of acute leukemias, lymphomas, rheumatoid arthritis, and inflammatory bowel disease, such as Crohn's Disease and ulcerative colitis, respectively.


Mercaptopurine has the following structure:



Azathioprine is the main immunosuppressive cytotoxic substance. It is widely used in transplantations to control rejection reactions. It is nonenzymatically cleaved to 6-mercaptopurine that acts as a purine analogue and an inhibitor of DNA synthesis. By preventing the clonal expansion of lymphocytes in the induction phase of the immune response, it affects both the cell and the humoral immunity. It also successfully suppresses autoimmunity. Azathioprine has the following structure:




Thioguanine used during early and/or late intensification therapy of childhood acute lymphoblastic leukemia (ALL) while 6-mercaptopurine is mainly used at a different time point of therapy, namely during maintenance treatment of ALL. Thioguanine has the following structure:



Fludarabine or fludarabine phosphate (Fludara®) is a chemotherapy drug used in the treatment of chronic lymphocytic leukemia and indolent non-Hodgkins lymphomas. Fludarabine is a purine analog. Fludarabine inhibits DNA synthesis by interfering with ribonucleotide reductase and

DNA polymerase and is S phase-specific (since these enzymes are highly active during DNA replication). Fludarabine has the following structure:



“FLU” when used herein means fludarabine.

“VH” refers to the variable region of an immunoglobulin heavy chain of an antibody, or antibody fragment. “VL” refers to the variable region of the immunoglobulin light chain of an antibody, or antibody fragment.

The term “CD19” refers to the protein known as CD19, having the following synonyms: B4, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, CVID3, Differentiation antigen CD19, MGC12802, and T-cell surface antigen Leu-12.

Human CD19 has the amino acid sequence of:

```
MPPPRLLFFLLFLTPMEVRPEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSL
GLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGELFRWNVSDLG
GLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSLNQSLSQDLTMAPGS
TLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMWVMTGLLLPRATAQDAGK
YYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYLIFCLCSLVGILHLQRALVLRKRK
RMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTSGLGRAQRWAAGLGGTAPSYGNPSSDVQA
DGALGSRSPPGVGPEEEEEEGEYEEP DSEEDSEFYENDSNLGQDQLSQDGSYENPEDEPLGPE
DEDSFSNAESYENEDEELTQPVARTMDFLSPHGS AWDP SREATSLGSQSYEDMRGILYAAPQLR
SIRGQPGPNHEEDADSYENMDNPDGPDP AWGGGGRMGTWSTR. (SEQ ID NO: 7)
```

“MOR208” is an anti-CD19 antibody. The amino acid sequence of the variable domains is provided in Figure 3. The amino acid sequence of the heavy and light chain Fc regions of MOR208 is provided in Figure 4. “MOR208” and “XmAb 5574” are used as synonyms to describe the antibody shown in Figures 3 and 4. The MOR208 antibody is described in US patent application serial number 12/377,251, which is incorporated by reference in its entirety.

Additional antibodies specific for CD19 are described in US patent no. 7,109,304 (Immunomedics), which is incorporated by reference in its entirety; US application serial no. 11/917,750 (Medarex), which is incorporated by reference in its entirety; US application serial no. 11/852,106 (Medimmune), which is incorporated by reference in its entirety; US application serial no.

11/648,505 (Merck Patent GmbH), which is incorporated by reference in its entirety; US patent no. 7,968,687 (Seattle Genetics), which is incorporated by reference in its entirety; and US application serial no. 12/710,442 (Glenmark Pharmaceuticals), which is incorporated by reference in its entirety.

“Fc region” means the constant region of an antibody, which in humans may be of the IgG1, 2, 3, 4 subclass or others. The sequences of human Fc regions are available at IMGT, Human IGH C-REGIONS, http://www.imgt.org/IMGTrepertoire/Proteins/protein/human/IGH/IGHC/Hu_IGHCgenes.html (retrieved on 16 May 2011).

“RefmAb33” is an antibody whose amino acid sequence is as follows:

Heavy chain including the Fc region:

QVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKH
YNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSSASTKG
PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTV
PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMIS
RTPEVTCVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE
YKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTTPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
(SEQ ID NO: 8)

Light chain including the Fc region:

DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRF
SGSGSGTEFTLTISLQPDFFATYYCFQSGSGYPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT
ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYAC
EVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 9)

RefmAb33 is specific for RSV, and is used as isotype control, as it shares the same Fc region as MOR208.

A “combination” means more than one item, e.g. a compound such as an antibody and fludarabine.

The present disclosure also relates to combinations, pharmaceuticals, and pharmaceutical compositions containing the described combinations. The two components of the synergistic combination of the present invention, e.g. the antibody specific for CD19 and fludarabine, may be administered together, simultaneously or separately. When administered together, the two components may be formulated together in one pharmaceutical composition, which may include a pharmaceutical acceptable carrier or excipient. Alternatively the two components might also be formulated in different pharmaceutical compositions. In this case the two components can be administered simultaneously or subsequently. In an embodiment, fludarabine, is administered prior to and/or separately from the administration of the antibody specific for CD19, e.g. MOR208.

A pharmaceutical composition includes an active agent, eg. an antibody for therapeutic use in humans. A pharmaceutical composition may include acceptable carriers or excipients.

"Administered" or "administration" includes but is not limited to delivery by an injectable form, such as, for example, an intravenous, intramuscular, intradermal or subcutaneous route or mucosal route, for example, as a nasal spray or aerosol for inhalation or as an ingestible solution, capsule or tablet.

A "therapeutically effective amount" of a compound or combination refers to an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease or disorder and its complications. The amount that is effective for a particular therapeutic purpose will depend on the severity of the disease or injury as well as on the weight and general state of the subject. It will be understood that determination of an appropriate dosage may be achieved, using routine experimentation, by constructing a matrix of values and testing different points in the matrix, all of which is within the ordinary skills of a trained physician or clinical scientist.

The "CDRs" herein are defined by either Chothia et al or Kabat et al. See Chothia C, Lesk AM. (1987) Canonical structures for the hypervariable regions of immunoglobulins. *J Mol Biol.*, 196(4):901-17, which is incorporated by reference in its entirety. See Kabat E.A, Wu T.T., Perry H.M., Gottesman K.S. and Foeller C. (1991). *Sequences of Proteins of Immunological Interest*. 5th edit., NIH Publication no. 91-3242, US Dept. of Health and Human Services, Washington, DC, which is incorporated by reference in its entirety.

"Cross competes" means the ability of an antibody or other binding agent to interfere with the binding of other antibodies or binding agents to CD19 in a standard competitive binding assay. The ability or extent to which an antibody or other binding agent is able to interfere with the binding of another antibody or binding molecule to CD19, and, therefore whether it can be said to cross-compete according to the invention, can be determined using standard competition binding assays. One suitable assay involves the use of the Biacore technology (e.g. by using the BIAcore 3000 instrument (Biacore, Uppsala, Sweden)), which can measure the extent of interactions using surface plasmon resonance technology. Another assay for measuring cross-competing uses an ELISA-based approach. A high throughput process for "epitope binning" antibodies based upon their cross-competition is described in International Patent Application No. WO 2003/48731

The term "epitope" includes any protein determinant capable of specific binding to an antibody or otherwise interacting with a molecule. Epitopic determinants generally consist of chemically active surface groupings of molecules such as amino acids or carbohydrate or sugar side chains and can have specific three-dimensional structural characteristics, as well as specific charge characteristics. An epitope may be "linear" or "conformational." The term "linear epitope" refers to an epitope with all of the points of interaction between the protein and the interacting molecule (such as an antibody) occur linearly along the primary amino acid sequence of the protein (continuous). The term "conformational epitope" refers to an epitope in which discontinuous amino acids that come

together in three dimensional conformation. In a conformational epitope, the points of interaction occur across amino acid residues on the protein that are separated from one another.

"Binds the same epitope as" means the ability of an antibody or other binding agent to bind to CD19 and having the same epitope as the exemplified antibody. The epitopes of the exemplified antibody and other antibodies to CD19 can be determined using standard epitope mapping techniques. Epitope mapping techniques, well known in the art, include Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, New Jersey. For example, linear epitopes may be determined by e.g., concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports. Such techniques are known in the art and described in, e.g., U.S. Patent No. 4,708,871 ; Geysen et al, (1984) Proc. Natl. Acad. Sci. USA 8:3998-4002; Geysen et al, (1985) Proc. Natl. Acad. Sci. USA 82:78-182; Geysen et al, (1986) Mol. Immunol. 23 :709-715. Similarly, conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g., hydrogen/deuterium exchange, x-ray crystallography and two-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols, supra. Antigenic regions of proteins can also be identified using standard antigenicity and hydropathy plots, such as those calculated using, e.g., the Omega version 1.0 software program available from the Oxford Molecular Group. This computer program employs the Hopp/Woods method, Hopp et al, (1981) Proc. Natl. Acad. Sci USA 78:3824-3828; for determining antigenicity profiles, and the Kyte-Doolittle technique, Kyte et al, (1982) J.Mol. Biol. 157: 105-132; for hydropathy plots.

Embodiments

An aspect of the present disclosure comprises a combination of an antibody specific for CD19 and a purine analog for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia. In embodiments, the combination is synergistic.

Herein, the combination of the exemplified anti-CD19 antibody and fludarabine behaved synergistically in *in vitro* and *in vivo* models relevant to NHL and CLL. As both NHL and CLL are B cell related disorders and CD19 is highly expressed on B-cells, the exemplified combination should have the same mechanism of action and should also behave synergistically in the treatment of other B cell related disorders, e.g. ALL. Therefore, the combination of the exemplified antibody specific for CD19 and fludarabine will be effective in the treatment of humans in non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

As the mechanism of action of fludarabine and other purine analogs are similar, in that purine analogs interfere with the synthesis of nucleic acids, it is believed that synergy should also be seen

when treating humans having non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia with a combination of the exemplified anti-CD19 antibody and a purine analog other than fludarabine, e.g., mercaptopurine, azathioprine, and thioguanine.

As the exemplified anti-CD19 antibody and other anti-CD19 antibodies bind to the CD19 antigen, it is believed that synergy should also be seen when treating humans having non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia with a combination of any anti-CD19 antibody and a purine analog, where the anti-CD19 antibody is, for example, described in US patent application serial number 12/377,251 (Xencor), WO2005012493, WO2010053716 (Immunomedics); WO2007002223 (Medarex); WO2008022152 (Xencor); WO2008031056 (Medimmune); WO 2007/076950 (Merck Patent GmbH); WO 2009/052431 (Seattle Genetics); and WO2010095031 (Glenmark Pharmaceuticals), all of which are incorporated by reference in their entireties.

In embodiments, the antibody specific for CD19 comprises an antibody that cross-competes with the antibody comprising an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).

In embodiments, the antibody specific for CD19 comprises an antibody that binds to the same epitope as an antibody comprising an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).

In embodiments, the antibody specific for CD19 comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6)..

In embodiments, the antibody specific for CD19 comprises a variable heavy chain of the sequence EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTTYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGGQTLTVTSS (SEQ ID NO: 10) and a variable light chain of the sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYR

MSNLNSGVPDRFSGSGSGTEFTLTSSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK
(SEQ ID NO: 11).

In embodiments, the antibody specific for CD19 comprises a heavy chain constant domain of the sequence

5 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH
TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTC
PPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVE
VHNAKTKPREEQFNSTFRVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKG
QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPML
10 DSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK. (SEQ ID
NO: 12)

In embodiments, the antibody specific for CD19 comprises a light chain constant domain of the sequence

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT
15 EQDSKD STYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. (SEQ ID
NO: 13)

In embodiments, the purine analog is fludarabine.


In embodiments, the components of the combination, the antibody specific for CD19 and fludarabine, are administered separately. In an embodiment, fludarabine is
20 administered prior to administration of the antibody specific for CD19.

In embodiments the combination is a pharmaceutical composition. In embodiments, the composition comprises an acceptable carrier. In embodiments, the combination is administered in an effective amount.

In an aspect the synergistic combination of an antibody specific for CD19
25 comprising an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6) and
30 fludarabine is able to mediate killing of MEC-1 cells by ADCC in the presence of isolated human PBMCs with an at least two-fold, three-fold, four-fold, or five-fold better efficacy than fludarabine alone.

An aspect of the present disclosure comprises a synergistic combination of an antibody specific for CD19 comprising an HCDR1 region of sequence SYVMH (SEQ ID
35 NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence

RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6) and fludarabine for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia. In embodiments, the non-Hodgkin's lymphoma is



selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue, marginal zone, diffuse large B cell, Burkitt's, and mantle cell.

Another aspect comprises a method of treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia in an individual in need thereof, which method comprises administration of an antibody specific for CD19 and a purine analog. In embodiments of the method, the antibody specific for CD19 comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6). In embodiments of the method, the purine analog is fludarabine.

Examples

Example 1: Inhibition of proliferation of MEC-1 cells using MOR208 and fludarabine alone and in combination

Materials

MEC-1 cells: chronic B-cell leukemia cell line DSMZ# ACC497; Cell Medium: Iscove's Modified Dulbecco's Medium (IMDM) with GlutaMAX™, Invitrogen, Cat No.: 31980-048, 20% FCS; PBMCs: RPMI1640, with stabile Glutamine, PAN Biotech GmbH, Cat No.: P04-13500 supplemented with 10% FCS; Biocoll: Biochrome AG CAT No.: L6115 LOT No.: 1050T; Fludarabine: Bayer, 25 mg/ml in ddH₂O, LOT No.: 9100ST; and RefmAb33 (anti-RSV) with same Fc region as MOR208.

Methods

The cytotoxicity of MOR208 and fludarabine alone and in combination was tested in MEC-1 cells. FLU is a purine analog, therefore, functions via direct cytotoxicity in MEC-1 cells. MOR208 targets CD19 and additionally functions via ADCC in killing MEC-1 cells. For the following groups MEC-1 cell killing was measured: FLU at 18µg/ml; MOR208 at 66pm and the combination of MOR208 at 66pm and FLU at 18µg/ml. These concentrations were chosen as they are near or at the EC₅₀ for MOR208 and FLU.

In the FLU group and MOR208+FLU combination group, the MEC-1 cells were pre-incubated with FLU for 72 hours prior to the ADCC assay measurements. The MEC-1 cells were stained using 1mg/ml Calcein AM then counted and adjusted to 2X10⁵/ml. The PBMCs were counted and adjusted to 6X10⁶/ml. The ADCC assays were done as follows: Using 96 well plates, a 100µl cell suspension of MEC-1 cells was added per well, then 100µl cell suspension of PBMCs was added to

each well resulting in an E:T ratio of 30:1. The antibodies were diluted to 1 µg/ml in medium. Cells were centrifuged and re-suspended. To the target:effector cell-pellet 100 µl antibody solution or according control solution was added. The mixture was incubated for 4h in CO₂-incubator at 37 °C. The ADCC measurements were taken as follows: the incubated cell solution (~100 µl) was transferred into FACS tubes and 200 µl FACS buffer (DPBS + 3%FCS) and 0,5 µl PI stock solution was added to each tube. FACS-Calibur was used. Dead MEC-1 cells were stained with propidium iodide.

Table 1 and Figure 1 show the raw data.

Table 1

	control	MOR208 66pm	FLU 18µg/ml	FLU+MOR208 combination
Experiment 1	11	35,2	36,39	52,14
Experiment 2	19,5	29,8	38,48	46,9
Experiment 3	29,9	47,01	57,27	65,63

The values represent % dead cells. Each experiment represents PBMCs from different donors. The control used for Experiments 1 and 2 was RefMab33. The control used for Experiment 3, was PBMCs alone.

Table 2 shows the raw data of Table 1 normalized for specific killing and the results of the Chou calculations done in the determination of synergism.

Table 2

	Fludarabine 18 µg/ml	MOR208 66 pM	Flu + MOR208 (combination)	Chou Index
Experiment 1	0,6	0,6	1,0	0,03
Experiment 2	0,7	0,4	1,0	0,3
Experiment 3	0,8	0,5	1,0	0,3
Average	0,7	0,5	1,0	0,2

The values shown in Table 2 are calculated as follows: 1) from the raw data (% dead cells) shown in Table 1, the background (controls) were subtracted, resulting in the specific killing for each treatment group; then 2) the specific killing values were normalized by setting the combination of MOR208 + FLU to 1. The averages of Table 2 are depicted in Figure 5. Example ADCC dose

response curves used in the Chou factor calculations of the MOR208 + FLU combination are shown in Figure 2.

Chou Index (CI) calculations were completed in order to determine synergy of the combination of the exemplified anti-CD19 antibody and fludarabine as compared to MOR208 and FLU alone. The calculations are described in Ting-Chao Chou, Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies, Pharmacol Rev 58:621–681 (2006), which is incorporated by reference in its entirety and Chou TC, Talalay P, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55 (1984), which is incorporated by reference in its entirety. The methods of Chou-Talalay are carried out using the CI-isobol method.

Median-effect equation

The median-effect equation models the effect of an inhibitor (such as a drug) as $F_a/F_u = (D/D50)^m$, where D is the dose, F_a and F_u is the fraction of the system affected and unaffected by the dose D ($F_a + F_u = 1$); $D50$ is the dose producing the median effect (e.g. IC50, ED50, LD50). The constant m determines the shape of the dose-effect curve. We used Excel Fit software to carry out a linear regression calculation to estimate the parameters m and $D50$.

The effects of the combination on MEC-1 cells is measured % cell death as described above. We define the fraction F_u to be the ratio of % cell death of the treated cell line to the % cell death of the cell line exposed to a control. That is:

$$F_u = \% \text{ cell death (treated cell line)} / \% \text{ cell death (non-treated cell line)}$$

Then the % cell death of a cell line is the constant $D50$ in the median effect equation, which can be estimated by the linear regression described above.

CI-isobol method

The CI-isobol method provides a quantitative assessment of synergism between drugs. A combination index (CI) is estimated from dose-effect data of single and combined drug treatments. A value of CI less than 1 indicates synergism; CI = 1 indicates additive effect; and CI > 1 indicates antagonism. Drug interaction (synergism or antagonism) is more pronounced the farther a CI value is from 1.

Formally, the combination index (CI) of a combined drug treatment is defined as $CI = D_1/D_{x1} + D_2/D_{x2}$. Here D_1 and D_2 are the doses of drug 1 and drug 2 of the combination, respectively; and D_{x1} and D_{x2} is the dose of a treatment with only drug 1 and drug 2 that would give the same effect as that of the combination. The doses D_{x1} and D_{x2} need to be estimated from the dose-effect data of single drug treatments. Essentially, a median effect equation is fitted to the data of

each drug. From the median effect equation of a drug, we can estimate the dose (i.e. D) necessary to produce an effect (i.e. Fa, Fu). The further a point lies from the additive line, the bigger the difference between 1 and its CI, thus the stronger the (synergistic or antagonistic) effect is.

Results

As shown in Table 2, the Chou index values indicate clear synergism of the combination of MOR208 and fludarabine in the specific killing of MEC-1 cells as compared to MOR208 and fludarabine alone. This conclusion is based upon the Chou calculations of 0.03, 0.3 and 0.3 in each of the three experiments, respectively, with an average of 0.21, where a CI < 1 indicates synergism. Therefore, the combination of MOR208 and fludarabine will also behave synergistically in the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphoid leukemia (CLL), and/or acute lymphoblastic leukemia (ALL) in humans.

In order to confirm the results of the above Chou calculations, the normalized data of Table 2 was evaluated for statistical significance using the Bonferroni's Multiple Comparison Test. See James, et al, Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice, Blood, 114(27):5454-63 (Epub 2009 Oct 30), which is incorporated by reference in its entirety. The results are shown in Table 3.

Table 3

Bonferroni's Multiple Comparison Test	Mean Diff.	T value	Significant? (P < 0.05)	Summary
Fludarabine (18µg/ml) vs. FLU + MOR 208 combination	-0.3067	5.039	Yes	**
MOR208 (66pM) vs. FLU + MOR208 combination	-0.5167	8.490	Yes	***

** p < 0,01

*** p < 0,001

Results

As shown in Table 3, the Bonferroni's Multiple Comparison Test shows that the combination treatment of FLU + MOR208 is statistically more effective in the specific killing of MEC-1 cells than the treatment of FLU and MOR208 alone.

Example 2: MOR208 and FLU alone and in combination in subcutaneously (SC)-implanted human Ramos Burkitt's B-cell lymphoma tumor growth model.

Materials

RAMOS human Burkitt's lymphoma cells (ATCC number CRL-1596, lot# 3953138); Vehicle control: 0.9% sodium chloride, 25mg/ml mannitol, pH 7.0;; SCID Mice (University of Adelaide, Waite Campus, Urrbarraie, SA, Australia, Strain C.B.-17-Igh-1^b-Prkdc^{scid}).

Methods

Six-to-seven-week old female C.B-17 SCID mice were implanted sub-cutaneously with RAMOS cells ($\sim 5 \times 10^6$ cells/mouse). 14 days after inoculation, the mice were separated into ten groups of eight, where each group had tumor volumes of relatively the same size. Treatment began on Day 14. The treatment regimens are provided in Table 4. The study duration was 63 days.

Table 4

No. of Animals	Test Articles	Dose (mg/kg)	Treatment Route and Schedule
8	Fludarabine	125	IP, Q1Dx5
8	Fludarabine	250	IP, Q1Dx5
8	MOR208	1 [*] ->10	Dys 14 [*] , 17 [*] , 21 [*] , 24, 28, 31, 35, and 38
8	Vehicle		IP, Q1Dx5
8	MOR208/ Fludarabine	1 [*] ->10/ 125	Dys 14 [*] , 17 [*] , 21 [*] , 24, 28, 31, 35, and 38/ IP, Q1Dx5

MOR208, fludarabine, and the vehicle were administered in a volume of 0.1 mL/10 g of body weight. The initial readout was tumor growth, specifically tumor volume at study day 38. Tumor weights were calculated using the equation $(l \times w^2)/2$, where l and w refer to the larger and smaller dimensions collected at each measurement.

The results are shown in Table 5 and the averages are depicted in Figure 6.

Table 5

Tumor Volume [mm ³] at study day 38					
	Vehicle Control	MOR208 10 mg/kg	Fludarabine 125 mg/kg	Fludarabine 250 mg/kg	Combination: MOR208/FLU 125
Group 1	2890	2138	1666	1352	1268
Group 2	4400	2025	2560	1352	750
Group 3	4200	3179	864	2816	726
Group 4	4152	1764	1913	1764	446
Group 5	3791	1862	3564	650	936
Group 6	4513	3402	2560	787	1268
Group 7	4152	2560	2025	1800	787
Group 8		2816	1437	787	
Average	4014	2468	2073	1413	883

In addition to an endpoint of tumor volume at study day 38, the parameters of 1) reduced tumor growth [%] at day 38, and 2) increased time to 4000mg tumors [%] were evaluated. The results are shown in Table 6.

Table 6

Treatment Groups	Reduced tumor growth at study Day 38 (%)	Increased time to 4000mg [%]
MOR208	38.5	17.52
FLU 125	48.3	22.37
FLU 250	64.8	30.19
Combination of MOR208 and FLU 125	78	59.3
Control	0	0

Both of the endpoints shown in Table 6 were evaluated using the Fractional Product Concept (FPC) in order to determine if synergism existed with the treatment of the combination of MOR208 and FLU treatment as compared to MOR208 and Fludarabine alone. When the combination treatment group is more effective than the FPC calculation, then synergism exists. The Fractional Product Concept was calculated using the formula $1 - [(1-A) \cdot (1-B)] = \text{fpc}(\%)$, as described by Webb, J. L. (1963) Enzyme and Metabolic Inhibitors, Academic Press, New York, which is incorporated by

reference in its entirety. After the FPC calculations were completed, the resulting FPC value and the values from Table 6 were normalized by setting the FPC value to 1. The results of these calculations are shown in Table 7.

Table 7

	MOR208 [10 mg/kg]	Fludarabine [125 mg/kg]	Fludarabine [250 mg/kg]	Fractional Product combination	MOR208 + FLU 125 combination	Effect
Reduced tumor growth at study Day 38 (%)	0.57	0.75	0,9	1	1.15	Synergism
Increased time to 4000mg [%]	0.48	0.62	0,8	1	1.65	Synergism

Results

Both of the endpoints are a measure of inhibition of tumor growth and in both endpoints, reduced tumor growth (%) at study day 38 and increased time (%) to 4000mg, the combination of MOR208 + FLU125 showed clear synergism in comparison to MOR208 and FLU alone.

In order to confirm the results of the above FPC calculations, the data of average Tumor Volume [mm³] at study day 38 (shown in Table 5) was evaluated for statistical significance using the Bonferroni's Multiple Comparison Test. The results are shown in Table 8.

Table 8

<u>Treatment Group</u>	Bonferroni's Multiple Comparison Test; p value
FLU125 vs FLU125 + MOR208 (combination)	p < 0.01
FLU250 vs FLU125 + MOR208 (combination)	n.s.
MOR208 vs FLU125 + MOR208 (combination)	p < 0.001
Control vs. FLU125	p < 0.001
Control vs. FLU250	p < 0.001
Control vs. FLU125 + MOR208 (combination)	p < 0.001
Control vs. MOR208	p < 0.001

A p value of < 0.05 shows statistical significance.

Results

As shown in Tables 5 and 6, in all parameters, the combination of MOR208 and Fludarabine 125 mg/kg was more effective in the inhibition of tumor growth *in vivo* than MOR208 or Fludarabine alone. This increase in effectiveness of the combination of MOR208 and Fludarabine 125 mg/kg in the inhibition of tumor growth *in vivo* as compared to both MOR208 and Fludarabine alone was confirmed to be statistically significant, as shown in Table 8. In addition, the Fractional Product Concept calculations show clear synergism of combination of MOR208 and Fludarabine 125 mg/kg in the inhibition of tumor growth *in vivo* as compared to MOR208 or Fludarabine alone, as shown in Table 7. Therefore, the combination of MOR208 and fludarabine will also behave synergistically in the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphoid leukemia (CLL), and acute lymphoblastic leukemia (ALL) in humans.

In addition, the combination of MOR208 and Fludarabine 125 mg/kg was more effective in the inhibition of tumor growth *in vivo* than the higher dose Fludarabine 250 mg/kg alone. As fludarabine has shown significant side effects at higher doses, this result shows that a safer, more effective alternative to high dose of Fludarabine, is the combination of MOR208 and Fludarabine.

Example 3 MOR208 and fludarabine alone and in combination in human Non-hodgkin RAMOS tumor in SCID mice, survival model

Materials

Cyclophosphamide (Fluka, Buchs Switzerland, Lot. No. 07551661); Vehicle Control: 0.9% sodium chloride, 25mg/ml mannitol, pH 7.0; SCID Mice (University of Adelaide, Waite Campus, Urrbarraie, SA, Australia, Strain C.B.-17-lgh-1^b-Prkdc^{scid}); RAMOS human lymphoma cells (ATCC number CRL-2638).

Methods

SCID mice were pre-treated with Cyclophosphamide (18 mg/kg, i.p., twice daily) for two days prior to RAMOS cell inoculation (Day -5 and -4). On the day of inoculation (Day -3), the mice were separated into ten groups of eight mice each, and inoculated with 1×10^6 RAMOS cells each intravenously into the tail vein. The dosing regimen for each group is shown in Table 9 and commenced on Day 0. The study duration was three weeks.

Table 9: Dosing regimen

Group	Compound	Treatment	Intended Schedule
A	Fludarabine	125 mg/kg, i.p, in 10 mL/kg	Once daily (Day 0-5)
B	MOR208	3 mg/kg, i.v., in 10 mL/kg	Twice weekly for 3 weeks
C	Vehicle Control	i.p., 10 mL/kg	Once daily (Day 0-5)
AB	Fludarabine /MOR208	125 mg/kg, i.p; 3 mg/kg, i.v. in 10 mL/kg;	Once daily (Day 0-5) /twice weekly for 3 weeks
E	Fludarabine	250 mg/kg, i.p, in 10 mL/kg	Once daily (Day 0-5)

The readout was median survival time in days. In order to evaluate whether the effect of the combination as compared to the individual treatment groups was synergistic, the methods of Clark et al. were used.

Clarke et al. synergism

The method is described in Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents *in vivo* in breast cancer and other models, Breast Cancer Research and Treatment 46:255-278 (1997), which is incorporated by reference in its entirety.

The data is analysed in the following way:

Antagonistic $(AB)/C < (A/C) \times (B/C)$

Additive $(AB)/C = (A/C) \times (B/C)$

Synergistic $(AB)/C > (A/C) \times (B/C)$

where A is the treatment with MOR208; B is the treatment with FLU alone; C is the response to the treatment vehicle; AB is the combination of treatments A and B. The median survival time in days for each study group and the Clarke et al. analysis are shown in Table 10.

Table 10

	Median Survival Time (Days)
A = response to treatment MOR208	23,5
B = response to treatment FLU	22
C = response to treatment vehicle	18,5
AB = combination of treatments A and B	31
(AB)/C	1,675675676
	is bigger than
(A/C) x (B/C)	1,510591673
	= Synergism

Results

The combination of MOR208 and FLU showed clear synergism in median survival days as compared to MOR208 and FLU alone.

In order to confirm the results of the above synergism calculations, the median survival time in days of the combination of MOR208 and fluradabine 125 mg/kg was compared to MOR208 and fluradabine alone using the Mantel-Haenszel test [P value], and Gehan-Wilcoxon test [P value]. Results shown in Table 11.

Table 11

Treatment Group	Mantel-Haenszel test [P value]	Gehan-Wilcoxon test [P value]
FLU/MOR vs. FLU 125	0,0008	0,0012
FLU/MOR vs. MOR	0,0001	0,0004
FLU/MOR vs. FLU250	0,0011	0,0016
FLU/MOR vs. control	0,0001	0,0004
Control vs. FLU125	0,0061	0,0162
Control vs. FLU250	0,0061	0,0162
Control vs. MOR208	< 0.0001	0,0002

Results

Table 10 shows that the combination of MOR208 and Fludarabine 125 mg/kg synergistically increased the median survival time in the Burkitt's lymphoma SCID mouse model as compared to both MOR208 and Fludarabine alone. This increase of median survival time of the combination of

MOR208 and Fludarabine 125 mg/kg *in vivo* was confirmed to be statistically significant as compared to both MOR208 and Fludarabine alone, as shown in Table 11. Therefore, the combination of MOR208 and fludarabine will also behave synergistically in the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphoid leukemia (CLL), and acute lymphoblastic leukemia (ALL) in humans.

In addition, the combination of MOR208 and Fludarabine 125 mg/kg was more effective in increasing median survival time *in vivo* than the higher dose Fludarabine 250 mg/kg alone. As fludarabine has shown significant side effects at higher doses, despite its effectiveness, this result shows that a safer, more effective alternative to high dose Fludarabine, is the combination of MOR208 and Fludarabine.

It is to be understood that the description, specific examples and data, while indicating exemplary embodiments, are given by way of illustration and are not intended to limit the present invention. Various changes and modifications within the present invention will become apparent to the skilled artisan from the discussion, disclosure and data contained herein, and thus are considered part of the invention.

CLAIMS

1. A method for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia in a subject comprising administering to
5 the subject a synergistic combination of:
an antibody specific for CD19; and
fludarabine,
wherein the antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region
10 of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).
2. The method according to claim 1, for the treatment of non-Hodgkin's lymphoma.
15
3. The method according to claim 1, for the treatment of chronic lymphocytic leukemia.
4. The method according to claim 1, for the treatment of acute lymphoblastic
20 leukemia.
5. The method according to any one of the preceding claims, wherein the antibody comprises a variable heavy chain of the sequence
EVQLVESGGGLVKPGGSLKLSAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDG
25 TKYNEKFQGRVTISSDKSISTAYMELSSLRSEDAMYYCARGTYYYGTRVFDYWGGQ TLVTVSS (SEQ ID NO: 10) and a variable light chain of the sequence
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMS
NLNSGVPDRFSGSGSGTEFTLTISSELPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).
30
6. The method according to any one of the preceding claims, wherein the antibody comprises a heavy chain constant domain of the sequence
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE
35 LLGGPDVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVQFNWYVDGVEVHNAKTK
PREEQFNSTFRVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQ

VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPMLDSDGSF
FLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO: 12).

7. The method according to any one of the preceding claims, wherein the antibody
5 comprises a light chain constant domain of the sequence
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT
EQDSKD STYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. (SEQ ID
NO: 13).
- 10 8. The method according to any one of the preceding claims, wherein the antibody
specific for CD19 and the fludarabine are administered separately.
9. The method according to any one of the preceding claims, wherein the
fludarabine is administered prior to administration of the antibody specific for CD19.
- 15 10. The method according to any one of the preceding claims, wherein the
combination mediates killing of MEC-1 cells by ADCC in the presence of isolated
human PBMCs with an at least two-fold better efficacy than fludarabine alone.
- 20 11. The method according to any one of claims 1, 2 or 5 to 10, wherein the non-
Hodgkin's lymphoma is selected from the group consisting of follicular lymphoma, small
lymphocytic lymphoma, mucosa-associated lymphoid tissue lymphoma, marginal zone
lymphoma, diffuse large B cell lymphoma, Burkitt's lymphoma, and mantle cell
lymphoma.
- 25 12. The method according to claim 11, wherein the non-Hodgkin's lymphoma is
follicular lymphoma.
13. The method according to claim 11, wherein the non-Hodgkin's lymphoma is
30 small lymphocytic lymphoma.
14. The method according to claim 11, wherein the non-Hodgkin's lymphoma is
mucosa-associated lymphoid tissue lymphoma.
- 35 15. The method according to claim 11, wherein the non-Hodgkin's lymphoma is
marginal zone lymphoma.

16. The method according to claim 11, wherein the non-Hodgkin's lymphoma is diffuse large B cell lymphoma.
- 5 17. The method according to claim 11, wherein the non-Hodgkin's lymphoma is Burkitt's lymphoma.
18. The method according to claim 11, wherein the non-Hodgkin's lymphoma is mantle cell lymphoma.
- 10 19. Use of a synergistic combination of:
an antibody specific for CD19; and
fludarabine,
for the manufacture of a medicament for the treatment of non-Hodgkin's
- 15 lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia,
wherein the antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS
- 20 (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).

Figure 1
Cytotoxicity of MOR208 and FLU alone and in combination




Figure 2

ADCC Dose response curves




Figure 3

The amino acid sequence of the MOR208 Variable Heavy Domain is:
(The CDRs are bolded and underlined)

EVQLVESGGGLVKPGGSLKLSCAASGYTFT**SYVMHWVRQAPGKGLEWIGYINPY**
NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMY^YCAR**GTYYYGTRVFDYWG**
QGT^LLVTVSS (SEQ ID NO: 10)

The amino acid sequence of the MOR208 Variable Light Domain is:
(The CDRs are bolded and underlined)

DIVMTQSPATLSLSPGERATLSC**RSSKSLQNVNGNTYLY**WFQQKPGQSPQLLIY**R**
MSNLNSGV^PPDRFSGSGSGTEFTLTISSELPEDFAVYYC**MQHLEYPIT**FGAGTKLEIK (SEQ
ID NO: 11)

The amino acid sequence of the MOR208 HCDR1 is: SYVMH (SEQ ID NO: 1)

The amino acid sequence of the MOR208 HCDR2 is: NPYNDG (SEQ ID NO: 2)

The amino acid sequence of the MOR208 HCDR3 is: GTYYYGTRVFDY (SEQ ID NO:
3)

The amino acid sequence of the MOR208 LCDR1 is: RSSKSLQNVNGNTYLY (SEQ
ID NO: 4)

The amino acid sequence of the MOR208 LCDR2 is: RMSNLNS (SEQ ID NO: 5)

The amino acid sequence of the MOR208 LCDR3 is: MQHLEYPIT (SEQ ID NO: 6)

Figure 4**Sequence of Fc regions**

The amino acids sequence of the MOR208 heavy chain Fc region is:


ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT
HTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVQFN
WYVDGVEVHNAKTKPREEQFNSTFRVSVLTVVHQDWLNGKEYKCKVSNKAL
PAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEW
ESNGQPENNYKTTTPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
HNHYTQKSLSLSPGK (SEQ ID NO: 12)

The amino acids sequence of the MOR208 light chain Fc region is:

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS
QESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG
EC (SEQ ID NO: 13)

Figure 5

Normalized specific killing; SD; MEC-1 target cells pretreated with Fludarabine (Flu) for 72 h before ADCC; pool of 3 independent experiments with 3 different effector cell donors



The figure shows the averages from the data shown in Table 2.

Figure 6





Figure 7

Median Survival Time in SCID mouse model



SEQUENCE LISTING 505784013_1

<110> Mr phoSys AG
<120> Combinations and uses thereof
<150> EP11177660.5
<151> August 16, 2011
<150> US 61/523,862
<151> August 16, 2011
<160> 13
<170> BiSSAP 1.0

<210> 1
<211> 5
<212> PRT
<213> synthetic construct

<220>
<221> SOURCE
<222> 1..5
<223> /mol_type="protein"
/note="HCDR1"
/organism="synthetic construct"

<400> 1
Ser Tyr Val Met His
1 5

<210> 2
<211> 6
<212> PRT
<213> synthetic construct

<220>
<221> SOURCE
<222> 1..6
<223> /mol_type="protein"
/note="HCDR2 "
/organism="synthetic construct"

<400> 2
Asn Pro Tyr Asn Asp Gly
1 5

<210> 3
<211> 12
<212> PRT
<213> synthetic construct

<220>
<221> SOURCE
<222> 1..12
<223> /mol_type="protein"
/note="HCDR3 "
/organism="synthetic construct"

<400> 3
Gly Thr Tyr Tyr Tyr Gly Thr Arg Val Phe Asp Tyr
1 5 10

<210> 4
<211> 16

505784013_1

<212> PRT
 <213> synthetic construct

<220>
 <221> SOURCE
 <222> 1..16
 <223> /mol_type="protein"
 /note="LCDR1 "
 /organism="synthetic construct"

<400> 4
 Arg Ser Ser Lys Ser Leu G n Asn Val Asn G y Asn Thr Tyr Leu Tyr
 1 5 10 15

<210> 5
 <211> 7
 <212> PRT
 <213> synthetic construct

<220>
 <221> SOURCE
 <222> 1..7
 <223> /mol_type="protein"
 /note="LCDR2 "
 /organism="synthetic construct"

<400> 5
 Arg Met Ser Asn Leu Asn Ser
 1 5

<210> 6
 <211> 9
 <212> PRT
 <213> synthetic construct

<220>
 <221> SOURCE
 <222> 1..9
 <223> /mol_type="protein"
 /note="LCDR3 "
 /organism="synthetic construct"

<400> 6
 Met G n H s Leu G u Tyr Pro I l e Thr
 1 5

<210> 7
 <211> 556
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SOURCE
 <222> 1..556
 <223> /mol_type="protein"
 /note="CD19 "
 /organism="Homo sapiens"

<400> 7
 Met Pro Pro Pro Arg Leu Leu Phe Phe Leu Leu Phe Leu Thr Pro Met
 1 5 10 15
 G u Val Arg Pro G u G u Pro Leu Val Val Lys Val G u G u G y Asp
 20 25 30
 Asn Ala Val Leu G n Cys Leu Lys G y Thr Ser Asp G y Pro Thr G n
 35 40 45
 G n Leu Thr Trp Ser Arg G u Ser Pro Leu Lys Pro Phe Leu Lys Leu
 50 55 60
 Ser Leu G y Leu Pro G y Leu G y I l e H s Met Arg Pro Leu Ala I l e

505784013_1

65	Trp	Leu	Phe	Ile	Phe	70	Asn	Val	Ser	Gln	Gln	75	Met	Gly	Gly	Phe	Tyr	80	Leu
				85	Pro	Pro	Ser	Glu	Lys	Ala	Trp	Gln	Pro	Gly	Trp	Thr			
			100	Gly	Gly	Ser	Gly	Glu	Leu	Phe	Arg	Trp	Asn	Val	Ser	Asp			
			115	Gly	Gly	Oys	Gly	Leu	Lys	Asn	Arg	Ser	Ser	Glu	Gly	Pro			
			130	Ser	Ser	Pro	Ser	Gly	Lys	Leu	Met	Ser	Pro	Lys	Leu	Tyr	Val	Trp	Ala
			145	Lys	Asp	Arg	Pro	Glu	Ile	Trp	Glu	Gly	Glu	Pro	Pro	Oys	Leu	Pro	Pro
					165	Asn	Gln	Ser	Leu	Ser	Gln	Asp	Leu	Thr	Met	Ala	Pro		
					180	Gly	Ser	Thr	Leu	Trp	Leu	Ser	Oys	Gly	Val	Pro	Pro	Asp	Ser
					195	Arg	Gly	Pro	Leu	Ser	Trp	Thr	His	Val	His	Pro	Lys	Gly	Pro
					210	Leu	Leu	Ser	Leu	Glu	Leu	Lys	Asp	Asp	Arg	Pro	Ala	Arg	Asp
					225	Val	Met	Glu	Thr	Gly	Leu	Leu	Leu	Pro	Arg	Ala	Thr	Ala	Gln
					245	Gly	Lys	Tyr	Tyr	Oys	His	Arg	Gly	Asn	Leu	Thr	Met	Ser	Phe
					260	Glu	Ile	Thr	Ala	Arg	Pro	Val	Leu	Trp	His	Trp	Leu	Leu	Arg
					275	Gly	Trp	Lys	Val	Ser	Ala	Val	Thr	Leu	Ala	Tyr	Leu	Ile	Phe
					290	Oys	Ser	Leu	Val	Gly	Ile	Leu	His	Leu	Gln	Arg	Ala	Leu	Val
					305	Arg	Lys	Arg	Lys	Arg	Met	Thr	Asp	Pro	Thr	Arg	Arg	Phe	Phe
					325	Thr	Pro	Pro	Pro	Gly	Ser	Gly	Pro	Gln	Asn	Gln	Tyr	Gly	Asn
					340	Ser	Leu	Pro	Thr	Pro	Thr	Ser	Gly	Leu	Gly	Arg	Ala	Gln	Arg
					355	Ala	Gly	Leu	Gly	Gly	Thr	Ala	Pro	Ser	Tyr	Gly	Asn	Pro	Ser
					370	Val	Gln	Ala	Asp	Gly	Ala	Leu	Gly	Ser	Arg	Ser	Pro	Pro	Gly
					385	Pro	Glu	Glu	Glu	Glu	Gly	Glu	Gly	Tyr	Glu	Glu	Pro	Asp	Ser
					405	Asp	Ser	Glu	Phe	Tyr	Glu	Asn	Asp	Ser	Asn	Leu	Gly	Gln	Asp
					420	Ser	Gln	Asp	Gly	Ser	Gly	Tyr	Glu	Asn	Pro	Glu	Asp	Glu	Pro
					435	Pro	Glu	Asp	Glu	Asp	Ser	Phe	Ser	Asn	Ala	Glu	Ser	Tyr	Glu
					450	Asp	Glu	Glu	Leu	Thr	Gln	Pro	Val	Ala	Arg	Thr	Met	Asp	Phe
					465	Pro	His	Gly	Ser	Ala	Trp	Asp	Pro	Ser	Arg	Glu	Ala	Thr	Ser
					485	Ser	Gln	Ser	Tyr	Glu	Asp	Met	Arg	Gly	Ile	Leu	Tyr	Ala	Ala
					500	Leu	Arg	Ser	Ile	Arg	Gly	Gln	Pro	Gly	Pro	Asn	His	Glu	Glu
					515	Asp	Ser	Tyr	Glu	Asn	Met	Asp	Asn	Pro	Asp	Gly	Pro	Asp	Pro
					530	Gly	Gly	Gly	Gly	Arg	Met	Gly	Thr	Trp	Ser	Thr	Arg		
					545														

<210> 8

<211> 450

<212> PRT

<213> synt het i c const ruct

<220>

505784013_1

<221> SOURCE
 <222> 1..450
 <223> /mol_type="protein"
 /note="Heavy chain Ref mAb33"
 /organism="synthetic construct"

<400> 8
 G n Val Thr Leu Arg G u Ser G y Pro Al a Leu Val Lys Pro Thr G n
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Phe Ser G y Phe Ser Leu Ser Thr Al a
 20 25 30
 G y Met Ser Val G y Trp Ile Arg G n Pro Pro G y Lys Al a Leu G u
 35 40 45
 Trp Leu Al a Asp Ile Trp Trp Asp Asp Lys Lys His Tyr Asn Pro Ser
 50 55 60
 Leu Lys Asp Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn G n Val
 65 70 75 80
 Val Leu Lys Val Thr Asn Met Asp Pro Al a Asp Thr Al a Thr Tyr Tyr
 85 90 95
 Cys Al a Arg Asp Met Ile Phe Asn Phe Tyr Phe Asp Val Trp G y G n
 100 105 110
 G y Thr Thr Val Thr Val Ser Ser Al a Ser Thr Lys G y Pro Ser Val
 115 120 125
 Phe Pro Leu Al a Pro Ser Ser Lys Ser Thr Ser G y G y Thr Al a Al a
 130 135 140
 Leu G y Cys Leu Val Lys Asp Tyr Phe Pro G u Pro Val Thr Val Ser
 145 150 155 160
 Trp Asn Ser G y Al a Leu Thr Ser G y Val His Thr Phe Pro Al a Val
 165 170 175
 Leu G n Ser Ser G y Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
 180 185 190
 Ser Ser Ser Leu G y Thr G n Thr Tyr Ile Cys Asn Val Asn His Lys
 195 200 205
 Pro Ser Asn Thr Lys Val Asp Lys Lys Val G u Pro Lys Ser Cys Asp
 210 215 220
 Lys Thr His Thr Cys Pro Pro Cys Pro Al a Pro G u Leu Leu G y G y
 225 230 235 240
 Pro Asp Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
 245 250 255
 Ser Arg Thr Pro G u Val Thr Cys Val Val Val Asp Val Ser His G u
 260 265 270
 Asp Pro G u Val G n Phe Asn Trp Tyr Val Asp G y Val G u Val His
 275 280 285
 Asn Al a Lys Thr Lys Pro Arg G u G u G n Phe Asn Ser Thr Phe Arg
 290 295 300
 Val Val Ser Val Leu Thr Val Val His G n Asp Trp Leu Asn G y Lys
 305 310 315 320
 G u Tyr Lys Cys Lys Val Ser Asn Lys Al a Leu Pro Al a Pro G u G u
 325 330 335
 Lys Thr Ile Ser Lys Thr Lys G y G n Pro Arg G u Pro G n Val Tyr
 340 345 350
 Thr Leu Pro Pro Ser Arg G u G u Met Thr Lys Asn G n Val Ser Leu
 355 360 365
 Thr Cys Leu Val Lys G y Phe Tyr Pro Ser Asp Ile Al a Val G u Trp
 370 375 380
 G u Ser Asn G y G n Pro G u Asn Asn Tyr Lys Thr Thr Pro Pro Met
 385 390 395 400
 Leu Asp Ser Asp G y Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
 405 410 415
 Lys Ser Arg Trp G n G n G y Asn Val Phe Ser Cys Ser Val Met His
 420 425 430
 G u Al a Leu His Asn His Tyr Thr G n Lys Ser Leu Ser Leu Ser Pro
 435 440 445
 G y Lys
 450

<210> 9
 <211> 213

505784013_1

<212> PRT
 <213> synthetic construct

<220>
 <221> SOURCE
 <222> 1..213
 <223> /mol_type="protein"
 /note="Light chain Ref mAb33"
 /organism="synthetic construct"

<400> 9
 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Arg Val Gly Tyr Met
 20 25 30
 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
 35 40 45
 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60
 Gly Ser Gly Thr Gu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
 65 70 75 80
 Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
 85 90 95
 Phe Gly Gly Gly Thr Lys Val Gu Ile Lys Arg Thr Val Ala Ala Pro
 100 105 110
 Ser Val Phe Ile Phe Pro Pro Ser Asp Gu Gln Leu Lys Ser Gly Thr
 115 120 125
 Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Gu Ala Lys
 130 135 140
 Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Gu
 145 150 155 160
 Ser Val Thr Gu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
 165 170 175
 Thr Leu Thr Leu Ser Lys Ala Asp Tyr Gu Lys His Lys Val Tyr Ala
 180 185 190
 Cys Gu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
 195 200 205
 Asn Arg Gly Gu Cys
 210

<210> 10
 <211> 121
 <212> PRT
 <213> synthetic construct

<220>
 <221> SOURCE
 <222> 1..121
 <223> /mol_type="protein"
 /note="heavy chain "
 /organism="synthetic construct"

<400> 10
 Gu Val Gln Leu Val Gu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Val Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gu Trp Ile
 35 40 45
 Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Gu Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Ile Ser Ser Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Gu Leu Ser Ser Leu Arg Ser Gu Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg Gly Thr Tyr Tyr Tyr Gly Thr Arg Val Phe Asp Tyr Trp Gly
 100 105 110
 Gln Gly Thr Leu Val Thr Val Ser Ser

505784013_1

115

120

<210> 11
 <211> 112
 <212> PRT
 <213> synt het i c constr uct

<220>
 <221> SOURCE
 <222> 1..112
 <223> /mol _t ype="protei n"
 /note="li ght chai n "
 /organi sm="synt het i c constr uct "

<400> 11
 Asp Ile Val Met Thr G n Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Gu Arg Ala Thr Leu Ser Cys Arg Ser Ser Lys Ser Leu G n Asn Val
 20 25 30
 Asn Gly Asn Thr Tyr Leu Tyr Trp Phe G n G n Lys Pro Gly G n Ser
 35 40 45
 Pro G n Leu Leu Ile Tyr Arg Met Ser Asn Leu Asn Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Gu Phe Thr Leu Thr Ile
 65 70 75 80
 Ser Ser Leu Gu Pro Gu Asp Phe Ala Val Tyr Tyr Cys Met G n His
 85 90 95
 Leu Gu Tyr Pro Ile Thr Phe Gly Ala Gly Thr Lys Leu Gu Ile Lys
 100 105 110

<210> 12
 <211> 329
 <212> PRT
 <213> synt het i c constr uct

<220>
 <221> SOURCE
 <222> 1..329
 <223> /mol _t ype="protei n"
 /note="heavy chai n const ant domai n"
 /organi sm="synt het i c constr uct "

<400> 12
 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15
 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30
 Phe Pro Gu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45
 Gly Val His Thr Phe Pro Ala Val Leu G n Ser Ser Gly Leu Tyr Ser
 50 55 60
 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr G n Thr
 65 70 75 80
 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95
 Lys Val Gu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
 100 105 110
 Pro Ala Pro Gu Leu Leu Gly Gly Pro Asp Val Phe Leu Phe Pro Pro
 115 120 125
 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Gu Val Thr Cys
 130 135 140
 Val Val Val Asp Val Ser His Gu Asp Pro Gu Val G n Phe Asn Trp
 145 150 155 160
 Tyr Val Asp Gly Val Gu Val His Asn Ala Lys Thr Lys Pro Arg Gu
 165 170 175
 Gu G n Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val
 180 185 190
 His G n Asp Trp Leu Asn Gly Lys Gu Tyr Lys Cys Lys Val Ser Asn

505784013_1

```

      195      200      205
Lys Ala Leu Pro Ala Pro Gu Gu Lys Thr Ile Ser Lys Thr Lys Gly
210      215      220
G n Pro Arg Gu Pro G n Val Tyr Thr Leu Pro Pro Ser Arg Gu Gu
225      230      235      240
Met Thr Lys Asn G n Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245      250
Pro Ser Asp Ile Ala Val Gu Trp Gu Ser Asn Gly G n Pro Gu Asn
260      265      270
Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe
275      280      285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp G n G n Gly Asn
290      295      300
Val Phe Ser Cys Ser Val Met His Gu Ala Leu His Asn His Tyr Thr
305      310      315      320
G n Lys Ser Leu Ser Leu Ser Pro Gly Lys
      325

```

```

<210> 13
<211> 107
<212> PRT
<213> synt het i c const ruct

```

```

<220>
<221> SOURCE
<222> 1..107
<223> /mol _type="protei n"
      /note="light chain constant domai n"
      /organi sm="synt het i c const ruct"

```

```

<400> 13
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Gu
1      5      10      15
G n Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
20      25      30
Tyr Pro Arg Gu Ala Lys Val G n Trp Lys Val Asp Asn Ala Leu G n
35      40      45
Ser Gly Asn Ser G n Gu Ser Val Thr Gu G n Asp Ser Lys Asp Ser
50      55      60
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Gu
65      70      75      80
Lys His Lys Val Tyr Ala Cys Gu Val Thr His G n Gly Leu Ser Ser
85      90      95
Pro Val Thr Lys Ser Phe Asn Arg Gly Gu Cys
100      105

```